10-Q · June 16, 2026
Aimei Health Technology Co., Ltd's Q4 2026 10-Q filing reveals it reported a net income of $45,440, driven by interest income but with no revenue generated. Management continues to face significant operational…
Earnings analysis · 10-Q
AFJK earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not include income-statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so current-period financial trends cannot be assessed from the filing text provided. The…
Read full summary
The supplied 10-Q extract does not include income-statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so current-period financial trends cannot be assessed from the filing text provided. The principal disclosure is a material weakness: as of June 30, 2026, disclosure controls were not effective because of inadequate segregation of duties and insufficient written policies and procedures. The company also states that no legal proceedings were reported under Item 1 and that it is not required to provide risk factors under Item 1A.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Control weakness disclosed
As of June 30, 2026, management evaluated disclosure controls under Item 4 and concluded they were not effective because of a material weakness involving inadequate segregation of duties and insufficient written policies.
-
No legal proceedings reported
The filing states under Item 1 that there were no legal proceedings as of the reporting period.
-
No other information disclosed
The company reported under Item 5 that there was no other information requiring disclosure during the quarter.
What to watch
-
Material internal-control weakness
As of June 30, 2026, disclosure controls were not effective due to inadequate segregation of duties caused by limited personnel, plus insufficient written policies and procedures for accounting, IT, financial reporting, and record keeping.
-
No control remediation reported
The filing states in Item 4 that no changes occurred during the most recent fiscal quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting; therefore, the disclosed weakness had not been remediated in the supplied filing.
-
Risk-factor disclosure omitted
Under Item 1A, the company states that, as a smaller reporting company, it is not required to provide risk-factor disclosures, limiting the filing's update on company-specific risks.
Management's outlook
The provided 10-Q extract contains no quantitative revenue or EPS outlook. No guidance was provided in the filing sections supplied.
Earlier filings 4
10-K · May 4, 2026
Aimei Health Technology Co., Ltd, a blank check company, has filed its first 10-K after its IPO, reporting a net income of $1,059,768 for the year ended December 31, 2025. The company’s strategy centers on pursuing…
10-Q · November 18, 2025
Aimei Health (AFJK) remains a blank-check/SPAC with no operating revenue; Q3 2025 reported net income of $352,019 and EPS of $0.06 but key liquidity metrics deteriorated as the Trust Account fell to $45,443,570 from…
10-Q · August 13, 2025
Aimei Health (AFJK) remains a SPAC with no operating revenue; Q2 2025 net income was $424,970 (driven by $466,574 of interest income) producing diluted EPS of $0.07, unchanged vs. Q2 2024. The Trust Account fell to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.